CStone Pharmaceuticals (HKSE:02616) Cash-to-Debt : N/A (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CStone Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2023 was N/A.

The historical rank and industry rank for CStone Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

HKSE:02616' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.83 Med: 335.9 Max: No Debt
Current: 2.83

During the past 8 years, CStone Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 2.83. And the median was 335.90.

HKSE:02616's Cash-to-Debt is ranked worse than
62.49% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs HKSE:02616: 2.83

CStone Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for CStone Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CStone Pharmaceuticals Cash-to-Debt Chart

CStone Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

631.33

40.47

9.91

3.64

2.83

CStone Pharmaceuticals Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial									9.91	5.05	3.64	N/A	2.83

Competitive Comparison of CStone Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, CStone Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CStone Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's Cash-to-Debt falls into.

CStone Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CStone Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1122.951	/	(152.378	+	245.154)
	=	2.82

CStone Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

CStone Pharmaceuticals (HKSE:02616) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CStone Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CStone Pharmaceuticals (HKSE:02616) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CSPHF:USA PH4:Germany

Address

218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123

Website

https://www.cstonepharma.com

CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines